CHECKMATE-032

NCT01928394 📎

Regimen

Experimental
nivolumab 3 mg/kg, or nivolumab 1 mg/kg + ipilimumab 3 mg/kg, or nivolumab 3 mg/kg + ipilimumab 1 mg/kg

Population

Western patients with chemotherapy-refractory gastric, esophageal, or GEJ cancer (79% with >=2 prior lines)

Key finding

ORR: nivo 12% / nivo1+ipi3 24% / nivo3+ipi1 8%; 12-mo OS 39% / 35% / 24%

Source: PMID 30110194

Timeline

    Guideline citations

    • NCCN GASTRIC (p.44)
    • CSCO GASTRIC 2025 (p.73)⚠️ OCR source